-transparent.png){kind=logo}
Multidrug resistance resulting from expression of an energy-dependent drug efflux pump encoded by the human MDR1 gene is a major impediment to effective cancer therapy. Pharmacologic intervention aimed at inhibiting this multidrug transporter should improve existing chemotherapy of human cancer, but drug development has been delayed by the difficulty and expense of developing valid animal models. Using recombinant DNA technology, a transgenic mouse has been engineered whose bone marrow is protected from the toxic effects of chemotherapy by expression of the MDR1 gene. This animal system allows the rapid screening of drugs which inhibit the multidrug transporter and heralds a new era of using transgenic animals for pharmacologic screening.
G H Mickisch, and
I Pastan, and
M M Gottesman
September 2014,
The Journal of antimicrobial chemotherapy,
G H Mickisch, and
I Pastan, and
M M Gottesman
June 2005,
Transgenic research,
G H Mickisch, and
I Pastan, and
M M Gottesman
October 2022,
Vaccines,
G H Mickisch, and
I Pastan, and
M M Gottesman
January 2001,
Contributions to nephrology,
G H Mickisch, and
I Pastan, and
M M Gottesman
August 2002,
Nihon rinsho. Japanese journal of clinical medicine,
G H Mickisch, and
I Pastan, and
M M Gottesman
September 1998,
Nordisk medicin,
G H Mickisch, and
I Pastan, and
M M Gottesman
February 2006,
Genesis (New York, N.Y. : 2000),
G H Mickisch, and
I Pastan, and
M M Gottesman
January 1998,
Methods in enzymology,
G H Mickisch, and
I Pastan, and
M M Gottesman
January 2015,
Emerging infectious diseases,
G H Mickisch, and
I Pastan, and
M M Gottesman
May 2021,
Archives of virology,
